If proven safe and effective, the vaccine could help stop tick-borne disease that affect nearly half a million Americans every year.
RELATED: Are you risking Lyme disease? Here’s how to remove ticks
Pfizer and a French partner are launching a large clinical trial of an experimental vaccine that would be the first to prevent Lyme disease, the companies announced Monday.
If proven safe and effective, the vaccine, currently called VLA15, could be an important tool to stop the tick-borne disease that affects nearly half a million Americans a year. Although many people clear the infection with a course of antibiotics, others suffer for years from lingering symptoms.
» Subscribe to USA TODAY:
» Watch more on this and other topics from USA TODAY:
» USA TODAY delivers current local and national news, sports, entertainment, finance, technology, and more through award-winning journalism, photos, videos and VR.
#Pfizer #Lyme #France
The leading causes of ill health or early death are drug use disorders, heart disease, depression, lung cancer and Chronic Obstructive Pulmonary Disease (COPD). Most of the conditions that cause a high proportion of the early death or ill health are related to modifiable factors that affect health.Dec 24, 2021